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Objective: The clinical history of bone metastases and skeletal-related events (SREs) 
secondary to cancers is not well understood. In support of studies of the natural history of bone 
metastases and SREs in Danish prostate and breast cancer patients, we estimated the sensitivity 
and specificity of hospital diagnoses for bone metastases and SREs (ie, radiation therapy to 
the bone, pathological or osteoporotic fractures, spinal cord compression and surgery to the 
bone) in a nationwide medical registry in Denmark.
Study design and setting: In North Jutland County, Denmark, we randomly sampled 
100 patients with primary prostate cancer and 100 patients with primary breast cancer diag-
noses from the National Registry of Patients (NRP), during the period January 1st, 2000 to 
December 31st, 2000 and followed them for up to five years after their cancer diagnosis. We 
used information from medical chart reviews as the reference for estimating sensitivity, and 
specificity of the NRP International Classification of Diseases, 10th edition (ICD-10) coding 
for bone metastases and SRE diagnoses.
Results: For prostate cancer, the overall sensitivity of bone metastases or SRE coding in the 
NRP was 0.54 (95% confidence interval [CI]: 0.39–0.69), and the specificity was 0.96 (95% 
CI: 0.87–1.00). For breast cancer, the overall sensitivity of bone metastases or SRE coding in 
the NRP was 0.58 (95% CI: 0.34–0.80), and the specificity was 0.95 (95% CI: 0.88–0.99).
Conclusion: We measured the validity of ICD-10 coding in the Danish NRP for bone metas-
tases and SREs in prostate and breast cancer patients and found it has adequate sensitivity and 
high specificity. The NRP remains a valuable tool for clinical epidemiological studies of bone 
metastases and SREs.
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Introduction
Bone metastases are a serious cause of morbidity and mortality in cancer patients.1 
These pathological events are key elements in the clinical course of cancer and 
contribute significantly to the debilitating pain and mortality that can occur in patients 
with advanced malignancies.2 Spinal metastases can produce cord compression and 
severe neurological impairment.3 Furthermore, bone metastases are often associated 
with other skeletal-related events (SREs), such as pathologic fractures, which may 
impair ambulation and affect overall quality of life.3 While almost every malignancy Clinical Epidemiology 2009:1 102
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can develop bone metastases, it has been estimated that breast 
cancer, lung cancer, and prostate cancer account for more 
than 80% of such metastases.1 However, limited information 
is available on the clinical course of patients who develop 
bone metastases, largely due to scarcity of resources for 
longer term patient follow up.
Medical registries, including all cases of a particular 
health condition or health-related exposure, are important 
data sources for epidemiological and clinical research.4 Using 
data from a medical registry greatly increases the efficiency 
and cost-effectiveness of such research. The large size of 
many databases offers the potential for precise estimates 
of effect and the possibility of studying rare exposures or 
outcomes. Other advantages are the reduced likelihood of 
bias due to nonresponse and the diagnostic process,5,6 and 
the ability to provide information on effects that have long 
induction periods for registries that have long follow-up. The 
Danish National Registry of Patients (NRP) is an electronic 
medical registry. Past studies have measured the validity 
of diagnostic codes used to identify a variety of medical 
conditions.7 However, the validity of diagnosis codes for 
bone metastases and SREs secondary to cancer recorded in 
the NRP has not yet been assessed. We therefore estimated 
the sensitivity and specificity of recorded International Clas-
sification of Diseases, 10th edition (ICD-10) diagnoses of 
bone metastases and other SREs (ie, radiation therapy to the 
bone, pathological fractures, and spinal cord compression) in 
prostate and breast cancer patients in North Jutland County 
in Denmark, using data from medical chart reviews as the 
reference.
Materials and methods
Since 1968, a unique 10-digit civil registry number 
(CPR number) assigned to all Danish residents8 at birth or 
emigration by the Danish Civil Registration System has been 
used to keep updated daily electronic records on date of birth, 
gender, change of address, date of emigration, and changes 
in vital status. The entire Danish population is provided with 
tax-supported health care by the National Health Service, 
allowing free access to hospital care. Care of all cancer 
patients is provided by specialized oncology centers within 
public hospitals operating under the auspices of the Danish 
National Health Service. We linked national data on hospital 
diagnoses and medical records using the CPR number 
and identified patients diagnosed with prostate or breast 
cancer between January 1st, 2000 and December 31st, 2000 
residing in North Jutland County (total population ∼500,000 
inhabitants or 9% of the total Danish population).9
The national Registry of Patients
Since 1977, Danish counties have developed administrative 
information systems and used them routinely to monitor 
electronic data on hospital admissions, such as inpatient and 
emergency room visits, dates of admission and discharge, 
discharge diagnosis, any surgical procedure performed, and 
treatments. Data from these systems are transferred to the 
NRP, which contains 99.4% of all discharge records from 
Danish hospitals. Since 1994, information has been coded 
according to the ICD-10,10 and since 1995, outpatient visits 
were also included.
Identification of patients with prostate 
and breast cancer in the nRP
We randomly selected 100 patients with a first-time diagnosis 
of prostate cancer (ICD-10 code C61.9) and 100 patients with 
a first-time diagnosis of breast cancer (ICD-10 code C50.xx) 
registered in the North Jutland NRP from January 1st, 2000 
to December 31st, 2000 (the positive predictive value of an 
ICD-10 breast cancer and prostate cancer code in the NRP 
has been estimated to be 98% and 96%, respectively).11 We 
followed these patients until death or for five years, and 
recorded all diagnoses and diagnosis dates of bone metas-
tases and SREs in the NRP. We used ICD-10 code C79.5 
to identify bone metastases. To identify pathological and 
osteoporotic fractures, we used the following codes: BWGC1 
(radiation to the bone), M80.0 (fractures of the vertebrae), 
M84.4 (fractures of the ribs and pelvis), M90.7 (fractures of 
femur and distal forearm), M43.9, M48.5, M54.5, M54.6, 
M54.9, G95.2, and G95.8 (spinal cord compression), and 
KNAGxx (bone surgery). We compared our records from 
the NRP with the information on bone metastases and SREs 
from the patients’ medical records.
statistical analyses
We used information from patients’ medical records (all 
records were available) as a reference for validating the 
NRP’s electronic records. We registered the particular 
event of either a bone metastases or/and a SRE at first 
date, it was mentioned in the medical record. We allowed 
a three-month time window between the diagnosis date in 
the medical records and the diagnosis date recorded in the 
electronic record in the NRP, because of potential delay in 
diagnosis coding after patients’ discharge. We only allowed 
a three-month time window to be sure that the NPR code 
corresponded to the episode found in the medical record.
The sensitivity of the ICD-10 coding for bone metastases 
and/or SREs was calculated as the proportion of patients who Clinical Epidemiology 2009:1 103
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had the diagnoses codes recorded for bone metastases and/or 
SREs in the NRP among all patients who had bone metastases 
and/or SREs according to the chart review.5 The specificity 
was calculated as the proportion of patients who did not 
have the diagnoses codes recorded for bone metastases 
and/or SREs in the NRP among all patients who did not 
have the diagnoses codes recorded for bone metastases 
and/or SREs according to the medical chart review.5 We 
further calculated the positive predictive value (PPV) and 
the negative predictive value (NPV) for a diagnosis of bone 
metastases and SREs in the NRP compared with the results 
from the chart review. The PPV was the proportion of patients 
registered with a bone metastases and/or SRE in the NRP, 
who also had this according to their medical record. The 
NPV was the proportion of patients not registered with a 
bone metastases and/or SRE in the NRP, who also did not 
have this according to their medical record. All estimates are 
presented with 95% confidence intervals (CI).12
We further estimated the impact of misclassification,13 
using the sensitivity measures of bone metastases and SREs 
(obtained from the analyses described above) on given rela-
tive risk estimates, assuming that the Danish NRP was used 
to identify cancer patients with bone metastases and/or SREs 
in a cohort and case-control design. In these analyses, we 
assumed the misclassification of bone metastases and SREs 
in the cancer patients to be nondifferential with respect to 
the exposure and outcome.
Statistical analyses were performed with STATA® 
software (version 9.2, STATA, College Station, TX, 
USA). The Danish Data Protection Agency approved the 
study.
Results
Prostate cancer
We followed 100 patients with a first-time prostate cancer 
diagnosis over five years who were registered in the NRP 
in the year 2000. The median age at diagnosis was 76 years 
(range: 45–92 years). During the follow-up period, 46 patients 
had a bone metastasis and/or a SRE diagnosis code recorded 
in their chart reviews (ie, the five-year incidence rate of bone 
metastases and/or SRE’s in these prostate cancer patients were 
46%). Of these 46 patients, 25 (54%) had a diagnosis recorded 
in both their chart review and the NRP. Thus, the sensitivity of 
the NRP was 0.54 (95% CI: 0.39–0.69). A total of 54 patients 
did not have a bone metastasis or SRE code recorded in their 
medical record, and of these 52 patients did not have a bone 
metastasis or SRE code recorded in the NRP, thus the NRP’s 
specificity was 0.96 (95% CI: 0.87–1.00). The corresponding 
PPV and NPV was 0.93 (95% CI: 0.76–0.99) and 0.71 
(95% CI: 0.59–0.81), respectively (Table 1).
For bone metastases alone, a total of 45 cases were 
recorded in the chart reviews. Of these, 20 (44%) cases 
were also recorded in the NRP, resulting in a sensitivity 
of 0.44 (95% CI: 0.30–0.60). A total of 55 patients did not 
have a bone metastasis recorded in their medical record, and 
all of these 55 patients also did not have a bone metastasis 
code recorded in the NRP, thus the NRP’s specificity for a 
bone metastases code was 1.00 (95% CI: 0.94–1.00). For 
SREs alone, a total of 29 cases were recorded in the medi-
cal chart reviews. Of these, 16 (55%) were also recorded 
in the NRP. Thus, for SREs the NRP had a sensitivity of 
0.55 (95% CI: 0.36–0.74). A total of 71 patients did not 
have a SRE code recorded in their medical record, and of 
these 67 patients did not have a SRE code recorded in the 
NRP, thus the NRP’s specificity for a SRE code was 0.94 
(95% CI: 0.86–0.98). The corresponding PPV and NPV was 
1.00 (95% CI: 0.83–1.00) and 0.69 (95% CI: 0.57–0.79), 
respectively (Table 1).
For  specific  SREs,  the  sensitivity  was  lower 
(range: 0.20–0.46), but the specificity remained high 
(range: 0.95–1.00). See Table 1 for further details.
Breast cancer
We followed 100 patients with a first-time breast cancer 
diagnosis over five years who were registered in the 
NRP in the year 2000. The median age at diagnosis was 
59.3 (range: 35–91 years). During the follow-up period, 
19 patients had either a bone metastasis or/and a SRE 
diagnosis code recorded in their chart reviews (ie, the 
five-year incidence rate of bone metastases and/or SRE’s in 
these breast cancer patients were 19%). Of these 19 patients, 
11 (58%) had a diagnosis recorded in both their chart review 
and the NRP. Thus, the sensitivity of the NRP was 0.58 (95% 
CI: 0.34–0.80). A total of 81 patients did not have a bone 
metastasis or SRE code recorded in their medical record, and 
of these 77 patients did not have a bone metastasis or SRE 
code recorded in the NRP, thus the NRP’s specificity was 
0.95 (95% CI: 0.88–0.99). The corresponding PPV and NPV 
was 0.73 (95% CI: 0.45–0.92) and 0.91 (95% CI: 0.82–0.96), 
respectively (Table 2).
For bone metastases alone, a total of 19 cases were 
recorded in the chart reviews. Of these, six (32%) cases 
were also recorded in the NRP, resulting in a sensitivity of 
0.32 (95% CI: 0.13–0.57). A total of 81 patients did not have 
a bone metastasis code recorded in their medical record, 
and of these 80 patients did not have a bone metastasis Clinical Epidemiology 2009:1 104
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Table 1 Validity of diagnoses codes of bone metastases and skeletal-related events (sREs) subsequent to prostate cancer in the Danish 
national Registry of Patients (nRP):  January 1st, 2000–December 31st, 2000
Medical chart review
NRP Yes No
Any bone metastases or sRE Yes 25 2
no 21 52
Total 46 54
sensitivity 25/46 = 0.54 (0.39–0.69)
Specificity: 52/54 = 0.96 (0.87–1.00)
PPV 25/(25 + 2) = 0.93 (0.76–0.99)
nPV 52/(52 + 21) = 0.71 (0.59–0.81)
Bone metastases only Yes 20 0
no 25 55
Total 45 55
sensitivity 20/45 = 0.44 (0.30–0.60)
Specificity: 55/55 = 1.00 (0.94–1.00)
PPV 20/(20 + 0) = 1.00 (0.83–1.00)
nPV 55/(55 + 45) = 0.69 (0.57–0.79)
Any sRE Yes 16 4
no 13 67
Total 29 71
sensitivity 16/29 = 0.55 (0.36–0.74)
Specificity: 67/71 = 0.94 (0.86–0.98)
PPV 16/(16 + 4) = 0.80 (0.56–0.94)
nPV 67/(67 + 13) = 0.84 (0.74–0.91)
Radiation therapy Yes 12 4
no 14 70
Total 26 74
sensitivity 12/26 = 0.46 (0.27–0.67)
Specificity: 70/74 = 0.95 (0.87–0.99)
PPV 12/(12 + 4) = 0.75 (0.48–0.93)
nPV 70/(70 + 14) = 0.83 (0.74–0.91)
Pathological fracture Yes 0 0
no 2 98
Total 2 98
sensitivity n/A
Specificity: 98/98 = 1.00 (0.96–1.00)
PPV n/A
nPV 98/(98 + 2) = 0.98 (0.93–1.00)
spinal cord compression Yes 2 0
no 8 90
Total 10 90
sensitivity 2/10 = 0.20 (0.03–0.56)
Specificity: 90/90 = 1.00 (0.96–1.00)
PPV 2/(2 + 0) = 1.00 (0.16–1.00)
nPV 90/(90 + 8) = 0.92 (0.85–0.96)
Abbreviations: nPV, negative predictive value; PPV, positive predictive value.Clinical Epidemiology 2009:1 105
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code recorded in the NRP, thus the NRP’s specificity was 
0.99 (95% CI: 0.93–1.00). For SREs alone, a total of 12 cases 
were recorded in the medical chart reviews. Of these, nine 
(75%) were recorded in the NRP. Thus, for SREs the NRP 
had a sensitivity of 0.75 (95% CI: 0.43–0.95). A total of 
88 patients did not have a SRE code recorded in their medical 
record, and of these 85 patients did not have a SRE code 
recorded in the NRP, thus the NRP’s specificity was 0.97 
(95% CI: 0.90–0.99). The corresponding PPV and NPV was 
0.86 (95% CI: 0.42–1.00) and 0.86 (95% CI: 0.77–0.92), 
respectively (Table 2).
For  specific  SREs,  the  sensitivity  was  lower 
(range: 0.33–0.75) but the specificity remained high (range: 
0.96–1.00). See Table 2 for further details.
sensitivity analyses
To estimate the impact of misclassification on relative 
risk estimates of the NRP for cancer patients with bone 
metastases and/or SREs in a cohort study, we simulated 
a study cohort of 200 cancer patients who were exposed 
to treatment A and 200 cancer patients who were exposed 
to treatment B. We followed these cancer patients for a 
period of five years. If the sensitivity of a bone metastasis 
and/or SRE was 0.75, which was the best case sensitivity 
estimate for breast cancer for the NRP obtained in the breast 
cancer analysis above, a true relative risk (RR) of 1.25 for 
bone metastasis and/or SREs among patients treated with 
treatment A compared with treatment B would still be 1.25. 
However, the incidence rate of bone metastasis and/or SREs 
would decline from 50% to 37.5% for patients on treatment 
A and from 40% to 30% for patients on treatment B. Using 
the worst case sensitivity estimate of 0.33 for pathological 
fractures among breast cancer patients in the NRP obtained 
in the breast cancer analysis above, the relative risk estimate 
would still be very close to the true RR, because the 
specificity of the bone metastasis and/or SREs diagnoses are 
high. However, the incidence rate of bone metastasis and/or 
SREs declined substantially in both treatment groups from 
50% to 16% for patients on treatment A and from 40% to 
13% for patients on treatment B.
We likewise simulated a case-control study of 200 cancer 
cases with bone metastasis and/or SRE, and 200 controls 
(cancer cases but without bone metastasis and/or SREs), 
and estimated the odds ratio (OR) for bone metastasis 
and/or SREs if cases and controls had a history of a given 
treatment (A or B). A true OR of 1.50 would decrease to 
1.40, if the sensitivity of a bone metastasis and/or SRE 
was 0.75. In the worst case (sensitivity estimate of 0.33), 
a true OR of 1.50 would decrease to 1.32. See Table 3 for 
further details.
Discussion
We followed 100 patients with prostate cancer and 
100 patients with breast cancer for at least five years to 
assess the validity of ICD-10 diagnosis codes of bone 
metastases and SREs in the Danish NRP, using medical 
chart reviews as a reference. Using this approach we were 
able to estimate the sensitivity and specificity of the NRP. 
The sensitivity of the diagnoses of bone metastases and 
SREs subsequent to prostate and breast cancer recorded in 
the NRP was adequate (although our results indicated that 
many patients who had either documented bone metastases 
and/or SRE’s did not have recorded ICD-10 codes in the 
NRP) compared with that documented for other validated 
diagnoses, while the specificity of bone metastases and 
SREs was high.7,14 Of further interest, we found these Danish 
prostate and breast cancer patients to have a high five-year 
incidence rate of bone metastases and/or SRE’s, which may 
partly be due to the fact that Denmark has no formal prostate 
and breast cancer screening program.
There are several potential explanations for the degree of 
under-coding we found in NRP records of bone metastases. 
Diagnostic procedures used to screen for bone metastases 
in breast and prostate cancer patients may depend on the 
patient’s expected prognosis. For instance, if a patient’s 
overall status is deemed inappropriate for radiation therapy or 
surgery (ie, poor prognosis) then there may be little incentive 
to code bone metastases. Additionally, the numeric ICD-10 
coding system is used to characterize obvious medical events; 
however, a bone metastasis may not be clinically obvious. 
Finally, reporting of bone metastases and SREs are not 
mandatory in Denmark, which may decrease the tendency 
for physicians and specialists to code these events.
Whether the data quality documented in our study is 
sufficient for registry-based studies depends on the proposed 
research questions and study design used.5 If NRP data are 
used to compare the occurrence of bone metastases and SREs 
over time (for instance, before and after introduction of a new 
treatment regimen), sensitivity and specificity should remain 
sufficiently stable. It is important that the misclassification of 
bone metastases or SREs is unrelated to information about 
earlier exposures or future outcomes (ie, nondifferential 
misclassification), if NRP data are used in cohort or case-
control studies. We expect this to be true for most exposures 
and outcomes. Our sensitivity analysis, illustrating the impact 
of misclassification on risk estimates if the NRP data were Clinical Epidemiology 2009:1 106
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Table 2 Validity of diagnoses codes of bone metastases and skeletal-related events (sREs) subsequent to breast cancer in the Danish 
national Registry of Patients (nRP): January 1st, 2000–December 31st, 2000
Medical chart review
NRP Yes No
Any bone metastases or sRE Yes 11 4
no 8 77
Total 19 81
sensitivity 11/19 = 0.58 (0.34–0.80)
Specificity: 77/81 = 0.95 (0.88–0.99)
PPV 11/(11 + 4) = 0.73 (0.45–0.92)
nPV 77/(77 + 8) = 0.91 (0.82–0.96)
Bone metastases only Yes 6 1
no 13 80
Total 19 81
sensitivity 6/19 = 0.32 (0.13–0.57)
Specificity: 80/81 = 0.99 (0.93–1.00)
PPV 6/(6 + 1) = 0.86 (0.42–1.00)
nPV 80/(80 + 13) = 0.86 (0.77–0.92)
Any sRE Yes 9 3
no 3 85
Total 12 88
sensitivity 9/12 = 0.75 (0.43–0.95)
Specificity: 67/71 = 0.97 (0.90–0.99)
PPV 9/(9 + 3) = 0.75 (0.43–0.95)
nPV 85/(85 + 3) = 0.97 (0.90–0.99)
Radiation therapy Yes 6 4
no 4 86
Total 10 90
sensitivity 6/10 = 0.60 (0.26–0.88)
Specificity: 86/90 = 0.96 (0.89–0.99)
PPV 6/(6 + 4) = 0.60 (0.26–0.88)
nPV 85/(86 + 4) = 0.94 (0.88–0.98)
Pathological fracture Yes 1 1
no 2 96
Total 3 97
sensitivity 1/3 = 0.33 (0.04–0.91)
Specificity: 96/97 = 0.99 (0.94–1.00)
PPV 1/(1 + 1) = 0.50 (0.01–0.99)
nPV 96/(96 + 2) = 0.98 (0.93–1.00)
spinal cord compression Yes 3 0
no 1 96
Total 4 96
sensitivity 3/4 = 0.75 (0.19–0.99)
Specificity: 96/96 = 1.00 (0.96–1.00)
PPV 3/(3 + 0) = 1.00 (0.29–1.00)
nPV 96/(96 + 1) = 0.99 (0.94–1.00)
Abbreviations: nPV, negative predictive value; PPV, positive predictive value.Clinical Epidemiology 2009:1 107
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to be used to identify cancer patients with bone metastases 
and/or SREs for a cohort design or a case control design, 
shows that (under the assumption of nondifferential misclas-
sification) the relative estimates in a cohort study would not 
be biased. The odds ratio, however, in a case control study 
would be biased towards conservative risk estimates. Dif-
ferential misclassification of the exposure according to bone 
metastasis and/or SRE status, or differential misclassifica-
tion of bone metastasis and/or SRE status according to the 
patients’ prognosis could result in a falsely high or a falsely 
low risk estimate associated with the exposure.15 The latter 
is likely the case when mortality among cancer patients is 
the outcome under study, because under-coding is most often 
seen in severely ill patients.16
It is a major advantage to be able to use existing data 
sources such as hospital registries with large amounts of 
information for research purposes.8 The advantages of 
using NRP over chart reviews are the increased efficiency 
and cost-effectiveness of such research, especially for large 
study populations. The sensitivity of the ICD-10 coding in 
the Danish NRP for bone metastases and SREs among pros-
tate cancer patients ranges between 0.44 and 0.55, and the 
specificity ranges between 0.94 and 1.00. The sensitivity of 
the ICD-10 coding in the Danish NRP for bone metastases 
and SREs among breast cancer patients ranges between 0.32 
and 0.75, and the specificity ranges between 0.94 and 0.99. 
Thus, the NRP remains a valuable tool for clinical epidemio-
logical studies of bone metastases and SREs because of its 
sufficient sensitivity and high specificity for these conditions 
in prostate cancer and breast cancer patients.
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